Double Blind Placebo Control Opipramol-Baclofen Treatment for Addiction
Launched by MINISTRY OF HEALTH, ISRAEL · Feb 22, 2017
Trial Information
Current as of July 21, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age will be 60-18, both sexes, seeking treatment in order to stop the consumption of materials
- Exclusion Criteria:
- • Did not include trial addicts with co-morbidity, kidney, heart, metabolic, neurological and psychiatric disorders (psychosis, chronic depression).
About Ministry Of Health, Israel
The Ministry of Health in Israel is a governmental agency responsible for ensuring the health and well-being of the nation's population through effective health policies, regulation, and oversight. As a clinical trial sponsor, the Ministry plays a pivotal role in advancing medical research and innovation by facilitating rigorous and ethical studies that aim to improve healthcare outcomes. It collaborates with various stakeholders, including academic institutions, healthcare providers, and private sector entities, to promote evidence-based practices and enhance public health initiatives. The Ministry is committed to upholding the highest standards of scientific integrity and patient safety in all clinical research endeavors.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bet Shemesh, , Israel
Patients applied
Trial Officials
Gal Yadid, PhD
Principal Investigator
Bar Ilan University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials